Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Stephanie M Barrows,1 Kelly Wright,1 Catherine Copley-Merriman,1 James A Kaye,2 Marc Chioda,3 Robin Wiltshire,4 Knut Martin Torgersen,5 Elizabeth T Masters6 1Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA; 2Epidemiology and Clinical Research, RTI Health Solutions, Walt...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	anaplastic lymphoma kinase ALK non–small cell lung cancer NSCLC carcinoma non–small cell lung Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c973b3d4d18e4605a9596ed5a4aca270
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c973b3d4d18e4605a9596ed5a4aca270
record_format	dspace
spelling	oai:doaj.org-article:c973b3d4d18e4605a9596ed5a4aca2702021-12-02T04:28:38ZSystematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer1179-2728https://doaj.org/article/c973b3d4d18e4605a9596ed5a4aca2702019-02-01T00:00:00Zhttps://www.dovepress.com/systematic-review-of-sequencing-of-alk-inhibitors-in-alk-positive-non--peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Stephanie M Barrows,1 Kelly Wright,1 Catherine Copley-Merriman,1 James A Kaye,2 Marc Chioda,3 Robin Wiltshire,4 Knut Martin Torgersen,5 Elizabeth T Masters6 1Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA; 2Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA; 3Medical Affairs, Pfizer, Inc., New York, NY, USA; 4Medical Affairs, Pfizer Limited, Walton Oaks, UK; 5Medical Affairs, Pfizer, Inc., Oslo, Norway; 6Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA Abstract: The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4–89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5–22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors. Keywords: ALK, non-small-cell lung cancer, NSCLC, carcinoma, non-small-cell lung  Barrows SMWright KCopley-Merriman CKaye JAChioda MWiltshire RTorgersen KMMasters ETDove Medical Pressarticleanaplastic lymphoma kinaseALKnon–small cell lung cancerNSCLCcarcinomanon–small cell lungNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 10, Pp 11-20 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	anaplastic lymphoma kinase ALK non–small cell lung cancer NSCLC carcinoma non–small cell lung Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	anaplastic lymphoma kinase ALK non–small cell lung cancer NSCLC carcinoma non–small cell lung Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Barrows SM Wright K Copley-Merriman C Kaye JA Chioda M Wiltshire R Torgersen KM Masters ET Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
description	Stephanie M Barrows,1 Kelly Wright,1 Catherine Copley-Merriman,1 James A Kaye,2 Marc Chioda,3 Robin Wiltshire,4 Knut Martin Torgersen,5 Elizabeth T Masters6 1Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA; 2Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA; 3Medical Affairs, Pfizer, Inc., New York, NY, USA; 4Medical Affairs, Pfizer Limited, Walton Oaks, UK; 5Medical Affairs, Pfizer, Inc., Oslo, Norway; 6Health Economics and Outcomes Research, Pfizer, Inc., New York, NY, USA Abstract: The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4–89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5–22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors. Keywords: ALK, non-small-cell lung cancer, NSCLC, carcinoma, non-small-cell lung
format	article
author	Barrows SM Wright K Copley-Merriman C Kaye JA Chioda M Wiltshire R Torgersen KM Masters ET
author_facet	Barrows SM Wright K Copley-Merriman C Kaye JA Chioda M Wiltshire R Torgersen KM Masters ET
author_sort	Barrows SM
title	Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
title_short	Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
title_full	Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
title_fullStr	Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
title_full_unstemmed	Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
title_sort	systematic review of sequencing of alk inhibitors in alk-positive non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/c973b3d4d18e4605a9596ed5a4aca270
work_keys_str_mv	AT barrowssm systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer AT wrightk systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer AT copleymerrimanc systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer AT kayeja systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer AT chiodam systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer AT wiltshirer systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer AT torgersenkm systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer AT masterset systematicreviewofsequencingofalkinhibitorsinalkpositivenonsmallcelllungcancer
_version_	1718401216775454720

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer

Ejemplares similares